Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.
Vilde D. Haakensen, MD, PhD
Advertisement
Articles by Vilde D. Haakensen, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 10/5/2026
2
Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
3
GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026
4
Armenia Grants First Marketing Authorizations to Botensilimab Plus Balstilimab in Previously Treated MSS mCRC
5